177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model
Abstract
:1. Introduction
2. Materials and Methods
2.1. Radiosynthesis of 177Lu-DOTA-ATPS mAb
2.2. Cancer Cell Culture and Xenograft Tumor Model
2.3. Cellular Uptake of 177Lu-DOTA-ATPS mAb in Various Cancer Cells
2.4. Specific Binding of 177Lu-DOTA-ATPS mAb in MKN-45 Cells
2.5. Competitive Binding of 177Lu-DOTA-ATPS mAb in MKN-45 Cells
2.6. 177Lu-DOTA-ATPS mAb Radioimmunotherapy in MKN-45 Cells
2.7. Biodistribution Study of Wild-Type Mice and MKN-45 Tumor Xenograft Models
2.8. Blocking Study of 177Lu-DOTA-ATPS mAb in MKN-45 Tumor-Bearing Mice
2.9. Radioimmunotherapy, Immunohistochemical Staining, and 18F-FDG-PET Imaging in MKN-45 Tumor-Bearing Mice
2.10. Statistical Analysis
3. Results
3.1. Labeling Efficiency and In Vitro Stability of 177Lu-DOTA-ATPS mAb
3.2. Cellular Uptake, Specific Binding, and Inhibition of 177Lu-DOTA-ATPS mAb
3.3. 177Lu-DOTA-ATPS mAb Radioimmunotherapy in MKN-45 Cells
3.4. Biodistribution of 177Lu-DOTA-ATPS mAb in Wild-Type Mice and MKN-45 Tumor Xenograft Models
3.5. Radioimmunotherapy, Immunohistochemical Staining, and 18F-FDG-PET Imaging in MKN-45 Tumor-Bearing Mice
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182–1186. [Google Scholar] [CrossRef]
- Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29, 15–18. [Google Scholar] [CrossRef]
- Moser, T.L.; Stack, M.S.; Asplin, I.; Enghild, J.J.; Hojrup, P.; Everitt, L.; Hubchak, S.; Schnaper, H.W.; Pizzo, S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 1999, 96, 2811–2816. [Google Scholar] [CrossRef]
- Kenan, D.J.; Wahl, M.L. Ectopic localization of mitochondrial ATP synthase: A target for anti-angiogenesis intervention? J. Bioenerg. Biomembr. 2005, 37, 461–465. [Google Scholar] [CrossRef]
- Moser, T.L.; Kenan, D.J.; Ashley, T.A.; Roy, J.A.; Goodman, M.D.; Misra, U.K.; Cheek, D.J.; Pizzo, S.V. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. USA 2001, 98, 6656–6661. [Google Scholar] [CrossRef]
- Chi, S.-J.L.; Wahl, M.L.; Mowery, Y.M.; Shan, S.; Mukhopadhyay, S.; Hilderbrand, S.C.; Kenan, D.J.; Lipes, B.D.; Johnson, C.E.; Marusich, M.F.; et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res. 2007, 67, 4716–4724. [Google Scholar] [CrossRef]
- Zhang, X.; Gao, F.; Yu, L.L.; Peng, Y.; Liu, H.H.; Liu, J.-K.Y.; Yin, M.; Ni, J. Dual functions of a monoclonal antibody against cell surface F1F0 ATP synthase on both HUVEC and tumor cells. Acta Pharmacol. Sin. 2008, 29, 942–950. [Google Scholar] [CrossRef]
- Park, B.N.; Lee, S.J.; Roh, J.H.; Lee, K.H.; An, Y.S.; Yoon, J.K. Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis. Mol. Imaging 2017, 16, 1536012117737399. [Google Scholar] [CrossRef]
- Park, B.N.; Kim, G.H.; Ko, S.A.; Shin, G.H.; Lee, S.J.; An, Y.S.; Yoon, J.K. Zr-89 Immuno-PET Targeting Ectopic ATP Synthase Enables In-Vivo Imaging of Tumor Angiogenesis. Int. J. Mol. Sci. 2019, 20, 3928. [Google Scholar] [CrossRef]
- Sharkey, R.M.; Goldenberg, D.M. Cancer radioimmunotherapy. Immunotherapy 2011, 3, 349–370. [Google Scholar] [CrossRef]
- Saravana-Bawan, B.; Bajwa, A.; Paterson, J.; McEwan, A.J.B.; McMullen, T.P.W. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin. Nucl. Med. 2019, 44, 719–727. [Google Scholar] [CrossRef]
- Yechiel, Y.; Chicheportiche, A.; Keidar, Z.; Ben-Haim, S. Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals. PET Clin. 2024, 19(3), 389–399. [Google Scholar] [CrossRef]
- Menon, S.R.; Mitra, A.; Chakraborty, A.; Tawate, M.; Sahu, S.; Rakshit, S.; Gaikwad, S.; Dhotre, G.; Damle, A.; Banerjee, S. Clinical Dose Preparation of [(177)Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [(177)Lu]LuCl(3) for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. Cancer Biother. Radiopharm. 2022, 37, 384–402. [Google Scholar] [CrossRef]
- Thakral, P.; Singla, S.; Yadav, M.P.; Vasisht, A.; Sharma, A.; Gupta, S.-M.K.; Bal, C.S.; Snehlata; Malhotra, A. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients. Indian J. Med. Res. 2014, 139, 544–554. [Google Scholar]
- Jensen, R.L.; Leppla, D.; Rokosz, N.; Wurster, R.D. Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery 1998, 42, 130–135; discussion 135–136. [Google Scholar] [CrossRef]
- Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [Google Scholar] [CrossRef]
- Lahti, S.; Ludwig, J.M.; Xing, M.; Sun, L.; Zeng, D.; Kim, H.S. In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study. PLoS ONE 2017, 12, e0174539. [Google Scholar] [CrossRef]
- Bhagwat, S.V.; Gokhale, P.C.; Crew, A.P.; Cooke, A.; Yao, Y.; Mantis, C.; Kahler, J.; Workman, J.; Bittner, M.; Dudkin, L.; et al. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: Distinct from rapamycin. Mol. Cancer Ther. 2011, 10, 1394–1406. [Google Scholar] [CrossRef]
- Jiang, X.L.; Zhang, Y.; Luo, C.L.; Wu, X.H. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo. Asian Pac. J. Cancer Prev. 2012, 13, 6463–6468. [Google Scholar] [CrossRef]
- Niu, T.; Fan, M.; Lin, B.; Gao, F.; Tan, B.; Du, X. Current clinical application of lutetium-177 in solid tumors (Review). Exp. Ther. Med. 2024, 27, 225. [Google Scholar] [CrossRef]
- Patell, K.; Kurian, M.; Garcia, J.A.; Mendiratta, P.; Barata, P.C.; Jia, A.Y.; Spratt, D.E.; Brown, J.R. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: A systematic review. Expert. Rev. Anticancer. Ther. 2023, 23, 731–744. [Google Scholar] [CrossRef]
- Becx, M.N.; Minczeles, N.S.; Brabander, T.; de Herder, W.W.; Nonnekens, J.; Hofland, J. A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients. Cancers 2022, 14, 5792. [Google Scholar] [CrossRef]
- Bhusari, P.; Vatsa, R.; Singh, G.; Parmar, M.; Bal, A.; Dhawan, D.K.; Mittal, B.R.; Shukla, J. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Int. J. Cancer 2017, 140, 938–947. [Google Scholar] [CrossRef] [PubMed]
- Ehlerding, E.B.; Lacognata, S.; Jiang, D.; Ferreira, C.A.; Goel, S.; Hernandez, R.; Jeffery, J.J.; Theuer, C.P.; Cai, W. Targeting angiogenesis for radioimmunotherapy with a (177)Lu-labeled antibody. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 123–131. [Google Scholar] [CrossRef] [PubMed]
- Hennrich, U.; Kopka, K. Lutathera((R)): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals 2019, 12, 114. [Google Scholar] [CrossRef]
- Fallah, J.; Agrawal, S.; Gittleman, H.; Fiero, M.H.; Subramaniam, S.; John, C.; Chen, W.; Ricks, T.K.; Niu, G.; Fotenos, A.; et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin. Cancer Res. 2023, 29, 1651–1657. [Google Scholar] [CrossRef] [PubMed]
- Parus, J.L.; Pawlak, D.; Mikolajczak, R.; Duatti, A. Chemistry and bifunctional chelating agents for binding (177)Lu. Curr. Radiopharm. 2015, 8, 86–94. [Google Scholar] [CrossRef]
- Suzuki, H.; Kannaka, K.; Uehara, T. Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies. Pharmaceuticals 2024, 17, 508. [Google Scholar] [CrossRef]
- Wu, C.; Kobayashi, H.; Sun, B.; Yoo, T.M.; Paik, C.H.; Gansow, O.A.; Carrasquillo, J.A.; Pastan, I.; Brechbiel, M.W. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med. Chem. 1997, 5, 1925–1934. [Google Scholar] [CrossRef]
- Milenic, D.E.; Garmestani, K.; Chappell, L.L.; Dadachova, E.; Yordanov, A.; Ma, D.; Schlom, J.; Brechbiel, M.W. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 2002, 29, 431–442. [Google Scholar] [CrossRef]
- Bailey, G.A.; Price, E.W.; Zeglis, B.M.; Ferreira, C.L.; Boros, E.; Lacasse, M.J.; Patrick, B.O.; Lewis, J.S.; Adam, M.J.; Orvig, C. H(2)azapa: A versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu. Inorg. Chem. 2012, 51, 12575–12589. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, A.; Azuma, K.; Ikeda, K.; Inoue, S. Mechanisms Underlying the Regulation of Mitochondrial Respiratory Chain Complexes by Nuclear Steroid Receptors. Int. J. Mol. Sci. 2020, 21, 6683. [Google Scholar] [CrossRef] [PubMed]
- Hartmann, J.T.; Haap, M.; Kopp, H.G.; Lipp, H.P. Tyrosine kinase inhibitors—A review on pharmacology, metabolism and side effects. Curr. Drug Metab. 2009, 10, 470–481. [Google Scholar] [CrossRef] [PubMed]
- Ahmadzadehfar, H.; Eppard, E.; Kurpig, S.; Fimmers, R.; Yordanova, A.; Schlenkhoff, C.D.; Gartner, F.; Rogenhofer, S.; Essler, M. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016, 7, 12477–12488. [Google Scholar] [CrossRef]
- Baum, R.P.; Kulkarni, H.R.; Singh, A.; Kaemmerer, D.; Mueller, D.; Prasad, V.; Hommann, M.; Robiller, F.C.; Niepsch, K.; Franz, H.; et al. Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget 2018, 9, 16932–16950. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Park, B.-N.; An, Y.-S.; Kim, S.-M.; Lee, S.-J.; Park, Y.-J.; Yoon, J.-K. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model. Antibodies 2024, 13, 51. https://doi.org/10.3390/antib13030051
Park B-N, An Y-S, Kim S-M, Lee S-J, Park Y-J, Yoon J-K. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model. Antibodies. 2024; 13(3):51. https://doi.org/10.3390/antib13030051
Chicago/Turabian StylePark, Bok-Nam, Young-Sil An, Su-Min Kim, Su-Jin Lee, Yong-Jin Park, and Joon-Kee Yoon. 2024. "177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model" Antibodies 13, no. 3: 51. https://doi.org/10.3390/antib13030051